Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLC-3010 + axitinib versus axitinib alone in second-line advanced clear cell renal cell carcinoma
KCT0010878Phase 2Recruiting
- Sponsor
- Yonsei University Health System
- Start
- Oct 2026
- Modality
- Small Molecules, Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SLC-3010, axitinib in clear cell renal cell carcinoma (ccRCC), sponsored by Yonsei University Health System. Started Oct 2026; status: recruiting.
02
Drugs
SLC-3010axitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on KCT0010878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010878.